<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/87D01A4B-04C9-42BB-9965-215579AF50E1"><gtr:id>87D01A4B-04C9-42BB-9965-215579AF50E1</gtr:id><gtr:name>National Institutes of Health Clinical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Pharmacology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/87D01A4B-04C9-42BB-9965-215579AF50E1"><gtr:id>87D01A4B-04C9-42BB-9965-215579AF50E1</gtr:id><gtr:name>National Institutes of Health Clinical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DCB0A98B-0396-4D46-B265-69C4DD448BA7"><gtr:id>DCB0A98B-0396-4D46-B265-69C4DD448BA7</gtr:id><gtr:firstName>Hendrik Willem</gtr:firstName><gtr:surname>van Veen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0401165"><gtr:id>BA42E66C-BC80-4F30-8C17-CA0D0874EE35</gtr:id><gtr:title>Molecular mechanism of drug transport by the human breast cancer resistance protein (ABCG2)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0401165</gtr:grantReference><gtr:abstractText>Multidrug transporters are very small molecular machines that are present at the surface of human cells and microorganisms. These ingenious machines bind structurally unrelated drugs and toxins at the inside of the cell, and then move these compounds to the outside of the cell. Hence, multidrug transporters act as drug pumps that are able to lower the drug concentration inside the cell to levels at which these drugs are inactive and useless. As drugs now have lost their therapeutic effect, the cell has become multidrug resistant. Multidrug transporters provide the cell with a defense mechanism against toxic compounds that are harmful. However, the activity of multidrug transporters also interferes with the drug-based control, termed chemotherapy, of human tumours and infectious pathogenic microorganisms, in which drugs are used that should kill the cell. This project focuses on the human breast cancer resistance protein (BCRP), which is one of the major drug pumps in human. Surprisingly, we have been able to functionally express BCRP in Lactococcus lactis, a harmless bacterium which is used in the production of yoghurts and cheeses, and which is very easy to handle. We will now study how BCRP recognizes and binds drugs, and how BCRP is able to move drugs out of the cell. This knowledge may allow us to rationally design new drugs that can poison or circumvent the activity of BCRP and related transporters to improve chemotherapy of human cancers.</gtr:abstractText><gtr:technicalSummary>Multidrug transporters mediate the extrusion of structurally unrelated drugs from prokaryotic and eukaryotic cells. As a result of this efflux activity, the cytoplasmic drug concentration in the cell is lowered to subtoxic levels, and, hence, cells become multidrug resistant. Multidrug transporters interfere with the chemotherapeutic treatment of cancers and infections by pathogenic microorganisms. This research proposal focuses on the breast cancer resistance protein (BCRP, also termed ABCG2). BCRP is an ATP-binding cassette (ABC) transporter containing a nucleotide-binding domain, followed by a membrane domain with 6 transmembrane spanning segments. The protein is thought to homodimerise to form a functional transporter with the 4 core domains. Surprisingly, our recent observations suggest that the membrane domain of BCRP (BCRP-MD) is functionally analogous to a protonmotive force-driven secondary-active multidrug/proton antiporter. This project will focus in more detail on the role of the protonmotive-force and ATP-binding/hydrolysis in BCRP-mediated drug translocation, and aims to identify residues that are involved in proton translocation and in dimerisation of BCRP. The project entails a multidisciplinary strategy involving molecular biology-based methods as well as biochemical and biophysical techniques. This strategy will add important new information about the molecular mechanism of this unique class of multidrug transporters, and may lead to the development of new modulators that could induce drug uptake by ABC-type multidrug transporters in drug-resistant cells through their ability to uncouple ATP binding/hydrolysis from multidrug efflux.</gtr:technicalSummary><gtr:fund><gtr:end>2009-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>179050</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health Clinical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Medical Oncology</gtr:department><gtr:description>Collaboration with Dr Susan Bates, NIH, WASHINGTON DC, USA</gtr:description><gtr:id>F4300EF9-A575-4999-A07C-B550A3C25864</gtr:id><gtr:impact>Outcomes were included in our published paper by Velamakanni et al in Molecular Pharmacology</gtr:impact><gtr:outcomeId>HHQGnzURrJP-1</gtr:outcomeId><gtr:partnerContribution>Dr Susan Bates (NIH) studied trafficking and surface expression of the mutants by confocal fluorescence microscopy.</gtr:partnerContribution><gtr:piContribution>My research focussed on biochemical properties of mutants of ABCG2</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Dr Tai-Ping Fan, Cambridge</gtr:description><gtr:id>E12BAD57-6FA1-4B37-B3E8-3BCBEF8BADBA</gtr:id><gtr:impact>We published a paper together</gtr:impact><gtr:outcomeId>54619bd44ed856.33813747-1</gtr:outcomeId><gtr:partnerContribution>We provides the ABCG2 test system</gtr:partnerContribution><gtr:piContribution>In thi scollaboration, we studied the effect of ginsenosides on the activity of ABCG2</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation by Postdoc</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>18B9CE43-83CB-4F7D-8683-4B2286B80E8D</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Talk had scientific impact</gtr:impact><gtr:outcomeId>54619e5a1c6af1.06749744</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National Science Week</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>84AC005D-E2E0-4926-9D0E-7CCE5B232699</gtr:id><gtr:impact>Gave talk for general pubic about role of ABCG2 in multidrug resistance of cancer cells.

Increased awareness about the importance of pharmacological/biochemical research</gtr:impact><gtr:outcomeId>1F34D1DBA28</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>151000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Project Grant</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>641E9D72-A59C-405C-8069-2E139DBDC9B4</gtr:id><gtr:outcomeId>A140DD3BC450</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>equilibrium binding assay for steroid binding to ABCG2 transporter</gtr:description><gtr:id>04F2EC73-8442-4BE3-9C15-DAD61361288E</gtr:id><gtr:impact>Our method facilitates the measurement of lipid binding to membrane transporters in detergent solution</gtr:impact><gtr:outcomeId>F53979F984F</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>steroid binding assay for ABCG2</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Various cell lines were produced that express ABCG2 tagged at N or C-terminus, as well as mutants that are affected in drug and steroid hormone transport</gtr:description><gtr:id>10F9B83A-F207-4AC4-B352-845C19E1BB7B</gtr:id><gtr:impact>Our strains facilitate biochemical studies on human ABCG2</gtr:impact><gtr:outcomeId>EAJnUMewWML</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ABCG2 mutants</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In this method, we are able to record the transport activity of purified membrane domain of ABCG2 in proteoliposomes in which the protein is functionally reconstituted. It allows a study of the transport mechanism with a degree of detail that cannot be obtained by studies in intact cells.</gtr:description><gtr:id>39FEDBC5-35DE-4980-9BC8-37D782A0157B</gtr:id><gtr:impact>This method can be applied on a large variety of multidrug transporters</gtr:impact><gtr:outcomeId>545fd8e434f183.69929896</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Transport assays in proteoliposomes</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Bacterial (Lactococcus lactis) cells expressing human ABCG2 and mutants derived thereof</gtr:description><gtr:id>6964CE92-D949-4352-BC9B-FE5FEFB0A455</gtr:id><gtr:impact>The bioenergetic properties of membrane transporters are easier to study in bacteria, where the levels of nucleotides and the magnitude and composition of electrochemical transmembrane gradients can be manipulated more easily. As current evidence suggests that certain human multidrug transporters also transport lipids, it is useful to express these transporters in a bacterial lipid environment which is very different from human, and which prevents that the transporters are virtually embedded in their lipid substrates. The latter situation makes a study of drug/lipid transport by ABCG2 more difficult.</gtr:impact><gtr:outcomeId>4A174E81D44</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ABCG2 expressing bacteria</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>With input from my current postdoc Dr Kelvin Agboh and based on work of an earlier postdoc Dr Saroj Velamakanni, we have established methods to measure electrical currents generated by single purified ATP-binding cassette membrane (ABC) transporters in planar bilayers. This sheds new light on the biochemical properties and reaction mechanisms of these proteins. We hope to publish this work in 2016</gtr:description><gtr:id>4B0B996B-B351-418C-A3A9-5890C0AF1B45</gtr:id><gtr:impact>The ABC transporters under study are members of a large ABC superfamily. It is therefore likely that this feature of ABC transporters is more widespread</gtr:impact><gtr:outcomeId>56dff2bd875450.40288680</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Electrophysiological recordings on single purified membrane transporters</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4D7D981F-E9D4-4EB1-AA2D-C2D3A5A2366F</gtr:id><gtr:title>The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e3bd53c935f643aab5b8c97e7f6e3f0"><gtr:id>3e3bd53c935f643aab5b8c97e7f6e3f0</gtr:id><gtr:otherNames>Hardwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>E40E1181594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B84F7B47-46E7-4110-8437-C52331376274</gtr:id><gtr:title>Metabolites of ginsenosides as novel BCRP inhibitors.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40adf277cdebdaa1cceb57dd629a1437"><gtr:id>40adf277cdebdaa1cceb57dd629a1437</gtr:id><gtr:otherNames>Jin J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>9AEF59BA056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>341924D0-E3A9-4DAD-8B75-1FC18FE67EE1</gtr:id><gtr:title>Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1.</gtr:title><gtr:parentPublicationTitle>Trends in biochemical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4beefff2a422472744246f1e9efeab9c"><gtr:id>4beefff2a422472744246f1e9efeab9c</gtr:id><gtr:otherNames>Gutmann DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0968-0004</gtr:issn><gtr:outcomeId>JnTxnRLPyrk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB5C3C74-F9F8-45BA-9AE8-B591E22D4ABB</gtr:id><gtr:title>ATP-dependent substrate transport by the ABC transporter MsbA is proton-coupled.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/573f5022b2bdd30e0ecb6241763d2a7e"><gtr:id>573f5022b2bdd30e0ecb6241763d2a7e</gtr:id><gtr:otherNames>Singh H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5851a4ffe9be21.23103209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3468081-E8BC-478F-9A0D-FCDF8F737B43</gtr:id><gtr:title>Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2).</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a98074ec0c7fda56f1222c197332a8c7"><gtr:id>a98074ec0c7fda56f1222c197332a8c7</gtr:id><gtr:otherNames>Janvilisri T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>A4B6DEF5AA1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>672D9759-DC69-4230-8D80-FB6DABE9EF4B</gtr:id><gtr:title>Molecular basis of multidrug transport by ABC transporters.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5cf23a2ebde7362a1149368464231f8"><gtr:id>a5cf23a2ebde7362a1149368464231f8</gtr:id><gtr:otherNames>Seeger MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>048A7B8A119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7C3C2D6-DEE2-41C4-9FE6-9C180503E0A4</gtr:id><gtr:title>New light on multidrug binding by an ATP-binding-cassette transporter.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cec2da304a300429c5aef5820fff63ad"><gtr:id>cec2da304a300429c5aef5820fff63ad</gtr:id><gtr:otherNames>Shilling RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn><gtr:outcomeId>CFA24566F97</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BD0A667-75B5-42F4-8A34-E0AE125CF4BF</gtr:id><gtr:title>Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids.</gtr:title><gtr:parentPublicationTitle>European journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ccaa3f6f2ecb37dfbc4bd33489d029b"><gtr:id>2ccaa3f6f2ecb37dfbc4bd33489d029b</gtr:id><gtr:otherNames>Cooray HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2999</gtr:issn><gtr:outcomeId>52BC342A38A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25EB203D-E239-4367-817C-B9FE36BC58D3</gtr:id><gtr:title>A functional steroid-binding element in an ATP-binding cassette multidrug transporter.</gtr:title><gtr:parentPublicationTitle>Molecular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75cd0b6b7c2503fca63a29849004427a"><gtr:id>75cd0b6b7c2503fca63a29849004427a</gtr:id><gtr:otherNames>Velamakanni S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0026-895X</gtr:issn><gtr:outcomeId>57E8A1A33CC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBDE311E-F5FC-430C-8091-AF69539E1EB3</gtr:id><gtr:title>Similarities between ATP-dependent and ion-coupled multidrug transporters.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3aa7f4514bcf8adf453437b072667050"><gtr:id>3aa7f4514bcf8adf453437b072667050</gtr:id><gtr:otherNames>Venter H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>D7D66BA069A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7585E0E2-8D6E-49A1-B7BD-DE7820C2DE89</gtr:id><gtr:title>A high-throughput method for membrane protein solubility screening: the ultracentrifugation dispersity sedimentation assay.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4beefff2a422472744246f1e9efeab9c"><gtr:id>4beefff2a422472744246f1e9efeab9c</gtr:id><gtr:otherNames>Gutmann DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>7C00FB346BA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CBE8160-6D28-46BE-B30C-CC1170F446B4</gtr:id><gtr:title>ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.</gtr:title><gtr:parentPublicationTitle>Journal of bioenergetics and biomembranes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75cd0b6b7c2503fca63a29849004427a"><gtr:id>75cd0b6b7c2503fca63a29849004427a</gtr:id><gtr:otherNames>Velamakanni S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0145-479X</gtr:issn><gtr:outcomeId>04E3B9191CD</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0401165</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>